Next Article in Journal
Mechanisms of Surfactin from Bacillus subtilis SF1 against Fusarium foetens: A Novel Pathogen Inducing Potato Wilt
Previous Article in Journal
α-Pheromone Precursor Protein Foc4-PP1 Is Essential for the Full Virulence of Fusarium oxysporum f. sp. cubense Tropical Race 4
Previous Article in Special Issue
Navigating the New Reality: A Review of the Epidemiological, Clinical, and Microbiological Characteristics of Candida auris, with a Focus on Children
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JoF
Volume 9
Issue 3
10.3390/jof9030366
jof-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021

by
Joel Dascalu
1,
Hiba Zaaroura
1,
Yael Renert-Yuval
2,
Ziyad Khamaysi
1,3,
Emily Avitan-Hersh
1,3,*,† and
Rivka Friedland
2,4,*,†
1
Department of Dermatology, Rambam Health Care Campus, Haifa 3525408, Israel
2
Pediatric Dermatology Unit, Schneider Children’s Medical Center of Israel, Petach Tikva 4920235, Israel
3
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525422, Israel
4
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Fungi 2023, 9(3), 366; https://doi.org/10.3390/jof9030366
Submission received: 27 February 2023 / Revised: 12 March 2023 / Accepted: 15 March 2023 / Published: 17 March 2023
(This article belongs to the Special Issue Fungal Infections in Children 2022)
Browse Figures
Versions Notes

Abstract

:
Pediatric tinea capitis displays a wide range of prevalence, with significant variability among populations. We retrospectively extracted the medical records of 456 pediatric patients diagnosed with tinea capitis during the years 2010–2021, from the dermatology outpatient clinics in two tertiary medical centers. Three species were isolated in 90% of patients: T. tonsurans, M. canis, and T. violaceum. While T. tonsurans presented a six-fold increase in incidence during the years 2019–2021, M. canis maintained stable incidence rates. Furthermore, terbinafine was the most efficient antifungal agent against T. tonsurans, achieving complete clinical clearance in 95% of patients, as compared to fluconazole (68%) and griseofulvin (38%) (p < 0.001). The mycological cure was recorded in 61/90 (68%) of patients with available data, at an average of 10 weeks. For patients with M. canis, griseofulvin and fluconazole were equally efficient (73% and 66%, respectively) (p = 0.44). Kerion was described in 36% and 14% of patients with T. tonsurans and M. canis, respectively, (p < 0.001). In conclusion, since 2019, there has been a significant increase in the prevalence of T. tonsurans, establishing this pathogen as the most common cause for tinea capitis in our population. Our data suggest that terbinafine is effective and presents high cure rates for tinea capitis in the pediatric population.

1. Introduction

Tinea capitis is a common infection of the hair and scalp that occurs primarily in children. Tinea capitis is caused by either anthropophilic, zoophilic, or less commonly, geophilic dermatophytes. Worldwide, Trichophyton violaceum and Trichophyton tonsurans are the most frequently isolated anthropophilic dermatophytes, while Microsporum canis is the most predominant zoophilic dermatophyte [1]. The disease poses a worldwide public health concern due to its great contagious potential, high economic burden, and significant cost of systemic treatments, blood test follow-up, and related adverse events [2]. Additionally, social stigmata may be a major related concern, when children with anthropophilic infection are restricted from attending schools, need to wear hats, or if hair loss and scarring occurs. Overall, children affected by tinea capitis reported a high impact of the disease on their quality of life, correlating with disease severity [3].
Tinea capitis is an extremely contagious infection with known multifactorial risk factors, including overcrowding, poor hygiene, cultural habits, heat, humidity, and socio-economic status. Prevalence rates and culprit organisms widely differ among regions of the world and are related to gender, climate, demographic, and socio-economic factors [2]. For example, in North America, Western Africa, and Eastern Asia, the most common fungi are T. tonsurans, Trichophyton soudanense, and T. violaceum, respectively [1,4]. Tinea capitis also shows variable incidence rates between different ethnicities of the same geographic region [4,5]. However, nation-based studies consistently reveal that males have a higher predisposition to tinea capitis, postulated to be partly related to shorter length of hair [1,4,5]. Worldwide, tinea capitis is more common in populations with poor hygiene and lower socio-economic status [1,2]. For example, children attending a public school are at a higher risk for tinea capitis as compared to children attending a private school [5]. The constant spread of the disease in highly populated areas is also affected by the rates of asymptomatic carriers which constitute a persistent reservoir [6].
Clinical presentations of tinea capitis vary with two major presentations: inflammatory and non-inflammatory. Non-inflammatory tinea capitis presents with mild erythema, broken hairs, and mild scaling. When the infection occurs within the hair shaft, causing an endothrix pattern, the clinical result will be broken hairs manifesting as “black dot” patches. The inflammatory phenotype includes erythematous indurated plaques with pustules, subcutaneous nodules, and sinuses with serous or purulent discharge. This phenotype is usually associated with dermatophytic infections outside the hair shaft (ectothrix). Inflammatory tinea capitis might result in cicatricial alopecia, which is less common in the non-inflammatory phenotype. A severe inflammatory reaction characterized by extensive purulent nodules and sinuses, thick scale, and systemic symptoms including fever and lymphadenopathy is known as kerion celsi. The lymph nodes most commonly involved are the posterior cervical and posterior auricular nodes. These systemic symptoms are helpful diagnostic clinical clues supporting the diagnosis of fungal infection of the scalp over similar dermatologic conditions causing erythema, scaling, or alopecia. A reactive, widespread eczematous rash can also accompany inflammatory tinea capitis. This is referred to as the Id reaction. This inflammatory presentation in both the scalp and the eczematous rash is due to the T-cell-mediated hypersensitivity reaction to the infection by dermatophytes [7]. The inflammatory response is most commonly seen in children ages 5 to 10 and is rare in infancy [8]. While non-inflammatory tinea capitis is usually caused by anthropophilic dermatophytes, inflammatory tinea capitis is usually the result of M. Canis infection [9].
Another clinical presentation is an asymptomatic carrier state, defined as a condition in which dermatophytes are isolated and identified in a mycological test, with the complete absence of associated clinical signs. The asymptomatic carrier state is most commonly described with anthropophilic species. The prevalence varies in different populations and depends on geographic distribution. For example, in South Africa, T. violaceum is endemic and the prevalence of the asymptomatic carrier state reaches up to 49% [1]. In the USA (where T. tonsurans is the most common pathogen), the carrier state ranges between 8% to 15% of the general population [1,10]. The asymptomatic carrier state is probably one of the etiologies for the continuous spread of T. tonsurans [1].
Although clinical manifestations and epidemiologic data are the basis for suspecting tinea capitis, establishing the diagnosis necessitates a positive result in at least one ancillary test such as direct microscopy of the scale of hair specimen showing fungal hyphae, fungal culture, or molecular biology techniques such as a polymerase chain reaction (PCR) assay aimed at fungal ribosomal DNA genes. Identifying the species of the involved dermatophyte allows the clinician to choose the most suitable treatment [11].
Previous reports suggest a high tinea capitis prevalence rate in Israel: the second highest rate in the Middle East [1]. While M. canis was the most common pathogen in previous reports, recent reports suggest a pathogenic shift towards T. tonsurans [12,13]. The reasons for the increased prevalence of Trichophyton infections are unclear and may be attributed to immigration and globalization [2]. The third most common pathogen, T. violaceum, is known as the most prominent pathogen in Ethiopia, where it is found in up to 87% of tinea capitis cases [1]. People of East African descent comprise 1–2% of Israel’s population, originating mainly from Ethiopia. Accordingly, T. violaceum was found as the most common pathogen in children of African origin in Israel, while minimal rates of this pathogen were found in other ethnicities [9]. Additional tinea capitis-related pathogens in the United States and France include Microsporum audouinii and Trichophyton soudanense. The latter were found as the culprit pathogenic fungi among immigrants of African origin [2].
The recognition and awareness of epidemiological trends of tinea capitis and the culprit dermatophytes have an impact on both preventive measures and the selection of antifungal treatment. Therefore, periodical re-assessments are vital to characterize these trends.
The therapeutic options of tinea capitis vary and include griseofulvin, terbinafine, and fluconazole. In the pediatric population, the treatment of tinea capitis is adjusted by the weight of the patient. Griseofulvin is given at a dosage of 20 mg/kg/day, fluconazole at a dosage of 6 mg/kg/day, and oral granules of terbinafine are given at a daily dosage of 125 mg, 187.5 mg, or 250 mg, adjusted to their weight category of under 25 kg, between 25 and 35 kg, or over 35 kg, respectively [14]. The treatment usually lasts for 6–8 weeks for griseofulvin and fluconazole, and it is shorter for terbinafine (usually 3–4 weeks) [14,15]. Additionally, treatment selection takes into consideration the patient’s age and the relevant pathogen. For example, terbinafine oral granules are authorized from the age of four in North America, but terbinafine is off-label for pediatric tinea capitis in Israel. Griseofulvin is FDA-approved for tinea capitis, while fluconazole is considered an off-label treatment in the USA and Europe [16]. Regarding efficacy, terbinafine was found to be more effective than griseofulvin for tinea capitis due to Trichophyton infections and specifically for T. tonsurans infection, while griseofulvin was found to be more effective for tinea capitis caused by M. canis [17]. Consideration should also be given to the evolving resistance to griseofulvin [17,18] and to the lack of availability of the drug in some countries [16]. Topical shampoos, including ketoconazole and selenium sulfide, are recommended as adjunctive therapeutic options [19]. As of today, at least in the USA, there are no consensus clinical guidelines for the treatment of pediatric tinea capitis, and a further analysis of tinea capitis management outcomes may contribute to current practices [20].
In this study, we examined the prevalence, epidemiology, etiology, and the therapeutic outcomes of pediatric tinea capitis in dermatology outpatient clinics in two tertiary medical centers, as recorded over the past 12 years, delineating the ever-changing pattern of pediatric tinea capitis and its response to treatment.

2. Materials and Methods

Included in the study were all consecutive patients aged less than 18 years, who were diagnosed clinically and mycologically to have tinea capitis between 2010 and 2021. We included patients from the outpatient clinics of two tertiary medical centers to better represent the epidemiology of tinea capitis in Israel: the Dermatology Department at Rambam Health Care Campus in northern Israel (70 patients) and Schneider Children’s Medical Center in the center of Israel (386 patients). Two hundred and sixty-six patients were also described in a previous study [12].
The tinea capitis diagnosis was confirmed by either culture or a PCR analysis in all cases. The PCR was performed as previously described by Sherman et al. [21]. A commercial kit (Dermadyn IVD dermatophyte detection kit, DYN diagnostics) was used. The kit identifies Candida albicans, Trichophyton interdigitale, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton rubrum, Trichophyton soudanense, Trichophyton violaceum, Trichophyton benhamiae, Trichophyton verrucosum, Microsporum canis, Microsporum audouinii, and Epidermophyton floccosum.
The following data were retrieved from patients’ files: age, gender, ethnicity, residence, clinical manifestations and distribution, microbiological results before and after treatments, treatments (including drug name and dosing regimen), and response. Response to treatment was determined as “complete clinical cure”, “partial response”, and “no response”. We defined the former two terms according to the presence or absence of residual erythema and scale following treatment. The mycological cure was defined as negative mycological testing (either negative culture or PCR analysis).
The data were transferred to Microsoft Office Excel and subjected to a statistical analysis by the StatPlus statistical package software (StatPlus Prov.7, AnalystSoft Inc., Alexandria, VA, USA). A Mann–Whitney U test was used to compare continuous variables with non-normal distributions. Categorical variables were compared using the chi-square test, with p < 0.05 considered significant. NS represented a statistically non-significant result.

3. Results

A total of 456 pediatric patients were identified with a confirmed diagnosis of tinea capitis between January 2010 and December 2021. Demographic characteristics are described in Table 1. Most of the patients in this cohort were aged 4 to 7 years (204, 45%), 69 (15%) were 8 to 10 years old, 106 (23%) patients were 0–3, and 70 (15%) patients were 11 years old or older.
The prevalence of each pathogen is described in Table 2. Remarkably, the prevalence of pediatric tinea capitis was stable between 2010 and 2018, but there was a marked increase in the total number of annual cases in the last three years (2019–2021). This rise is consistent with the increased prevalence of T. Tonsurans infections, which showed a parallel increasing trend (Figure 1). During this period (2019–2021), T. tonsurans was isolated in 57% of all positive microbiological samples, and overall, the majority of T. tonsurans cases (115/140, 82%) were diagnosed during these three years. Throughout the cohort, the occurrences of T. tonsurans infections were distributed equally among the different seasons, ranging between 23 and 28 cases per season (NS).
We observed a significant male predominance, similar to previous reports. While M. canis was detected equally in both genders (39–40% of the cases), T. tonsurans was about twice as common among male patients as compared to female patients and accounted for 37% of male tinea capitis and only 18% of tinea capitis in female patients. In contrast, T. violaceum showed the opposite trend and was about twice as common in females as compared to males (33% vs. 14%, respectively).
When comparing the rates of specific pathogens among the different ethnicities (Table 3), we found that M. Canis was more common than T. tonsurans in the Arab population. Sixty-one patients (58%) of Arab descent were infected by M. canis while twenty-three patients (22%) were infected by T. tonsurans. The Jewish Caucasians had similar rates of both pathogens, 112 (41%) and 108 (40%), respectively. T. violaceum was found in 76% of Ethiopian patients, a significantly higher rate than in patients of either Arab or Caucasian Jewish descent (10% and 8%, respectively).
Additionally, we studied the distribution of the pathogens in the different age groups (Figure 2). M. canis was more prevalent among the younger patient groups: of one hundred seventy-seven patients infected with M. canis, one hundred seventy (96%) were younger than 11 years, and only seven patients (4%) were 11–15 years old. None of the patients were older than 16 years when detected with M. canis-related tinea capitis. Conversely, T. tonsurans was more equally distributed between the age groups. Of 138 patients, between 25 and 35 patients were infected in each age group. However, when studying the overall tendencies, at the ages of 0–3 years and 4–7 years M. canis was more common than T. tonsurans, as opposed to similar frequencies for patients aged 8–10 years. In the group of older children aged 11 years or older, the prevalence of M. canis markedly decreased and T. tonsurans comprised the more common pathogen. Interestingly, in the age group of patients older than 16 years, T. tonsurans was the only pathogen causing tinea capitis in non-African patients.
Clinically, the presence of scales was the most commonly reported manifestation (n = 425, 96%), followed by alopecia (n = 393, 88%), erythema (n = 253, 57%), kerion (n = 95, 21%), and pustules (n = 82, 18%). Kerion celsi and pustules were recorded in 36% and 33% of T. tonsurans-infected patients, respectively. M. canis was less likely to involve kerion (14%, p < 0.001) and pustules (11%, p < 0.001). Similarly, T. violaceum infections also presented with a lower prevalence of kerion (16%, p = 0.001) and pustules (14%, p = 0.002) compared to T. tonsurans infection.
Data of the applied antifungal agent were available for 424 patients (Table 4). Patients were initially administered with either fluconazole (n= 217, 52%), griseofulvin (n = 158, 38%), terbinafine (n = 41, 10%), or itraconazole (n = 4, 1%). About half of the patients adhered to the follow-up recommendations for each treatment; therefore, data of the treatment responses were available for 222 patients (52%). Only four patients were treated with itraconazole and were therefore omitted from the interpretation of the results. Terbinafine showed the highest efficacy for T. tonsurans, achieving the best rate of complete clinical cure (19/20, 95%), as compared to fluconazole (30/44, 68%) and griseofulvin (5/13, 38%); p < 0.001. M. canis and T. violaceum also showed high complete response rates of 66–84% to both griseofulvin and fluconazole, with no significant difference between these therapeutics for each pathogen (p = 0.44 and p = 0.37 for M. canis and T. violaceum, respectively).
The overall duration of treatment ranged from 2 weeks to 8 months, with a median of 2 months. The median treatment duration for both fluconazole and griseofulvin was 2 months (ranging from 1 week to 8 months and 1 week to 7 months, respectively). The median treatment duration of terbinafine was 6 weeks (ranging from 1 week to 6 months), which was shorter than griseofulvin (p < 0.026) and fluconazole (p < 0.111). Only four patients were treated by itraconazole with the median treatment duration of 1 month (3 weeks to 3 months). Culture results following treatment were available for 90 patients, of whom 61 (68%) achieved the mycological cure, at an average of 10 weeks, and 29 patients (32%) required further treatment.

4. Discussion

In this study, we presented a cohort of pediatric patients with tinea capitis, over a period of 12 years in two tertiary medical centers located in different districts, and characterized the mycological trends, epidemiology, clinical presentation, and response to treatments.
Tinea capitis is a global public health issue affecting mostly children, adolescents, and young adults. Although certain pathogens are traditionally related to specific countries, pathogen shifts are described in many developed countries [17,22,23,24,25,26,27,28,29,30,31,32,33,34]. The variability in pathogen distribution necessitates local studies to identify trends and pathogens, and to direct treatment selection. Our large cohort demonstrated a significant increase in T. tonsurans infections during the years 2019–2021, which places it as the most common current cause of pediatric tinea capitis. Our previous data in Schneider Children’s Medical Center showed the emergence of a T. tonsurans outbreak in 2019 [12], and similar results were described by Shemer et al. [13]. Thus, the current study both reaffirms the epidemiological trend in an additional tertiary center, and it demonstrates a consistent trend of increased prevalence of T. tonsurans among our patients. Notably, during these years, M. canis showed no significant change in prevalence, and was still isolated in a considerable proportion of patients (24% of samples). These results suggest that the rise in T. tonsurans infections was not accompanied by a decrease in M. canis infection, and that M. canis is still a significant pathogen, as in other countries in the Middle East [9]. Therefore, it is possible that the increase in the number of cases of T. tonsurans infections in this cohort represents a local increase rather than a pathogen shift. Worldwide, T. tonsurans has been associated with several outbreaks in the pediatric population [35]. For example, in a recent single center study in Germany, a ten-fold increase in the number of tinea capitis cases due to T. tonsurans was found during 2019–2022 [36]. New emerging pathogens have also been described in other countries around the world, potentially reflecting migrating populations importing certain pathogens to new areas [24,30,31,33,34].
The presumed etiology of the significant increase in the prevalence of T. tonsurans is unclear. It might be attributed to improper disinfection of barbering tools [13,37,38]. Another explanation could be the rising prevalence of asymptomatic carriers in the household of an infected patient [39,40]. In one study, up to 44% of asymptomatic carriage was noted [39]. These asymptomatic carriers may partially explain the occurrence of infection in younger children who are not exposed to barbering tools. Another possible contributing factor is suboptimal treatment, either due to misdiagnosis, using solely topical agents, inadequate dosage, inadequate treatment duration, or low compliance [41]. Such asymptomatic carriage contributes to the spread of the infection among household members as well as to other families. The equal distribution of T. tonsurans incidence among all seasons implies that the rise is probably not a consequence of climate change. Additional studies to determine whether T. tonsurans changes its virulence factors and carrier properties are needed.
T. violaceum is known to be the dominant pathogen in North and East Africa [33], but in 2020, T. tonsurans was first reported as the predominant agent causing tinea capitis in Ethiopia [42]. The Ethiopian population in Israel accounts for less than 2% of the general population, yet patients of Ethiopian decent represent 16% of this cohort of pediatric tinea capitis [43]. Our study reiterates the high prevalence of T. violaceum as the most prominent pathogen in patients of Ethiopian descent (76%), as opposed to other ethnicities (8–10%). It is important to note that although 92% of the Ethiopian children in Israel were born in Israel and this population is well-immersed, we did not see a decrease in the prevalence of T. violaceum during the last decade, nor did we see a transition of this pathogen to the non-Ethiopian population [43]. This finding reinforces the hypothesis that some host factors have an impact on the probability of being infected by certain pathogens.
M. audouinii, which was previously reported as an additional major pathogen in African and Ethiopian populations, was rare in our study with only three cases, and none of them were from a person of African descent [44]. These findings raise again the question of whether an infection with a pathogen is exclusively dependent on geographic factors that mainly represent climate and humidity-related influences, or also on genetic predisposition and other host characteristics.
Our study also sheds light on the association of fungal pathogens with kerion celsi. Inflammatory tinea capitis was historically attributed to zoophilic dermatophyte infections [22]; however, during recent decades, T. tonsurans was also described as a cause for kerion and severe inflammatory responses [45,46]. In our study, over 40% of patients with tinea capitis due to T. tonsurans presented with either pustules or kerion upon physical examination. Interestingly, the prevalence of kerion was lower (14%) in the group of patients diagnosed with M. canis. The inflammatory phenotype can also be ascribed to a shift in the virulence of sub-strains of certain pathogens or to a different immunologic response of hosts from different genetic backgrounds, resulting in the varied susceptibility of some patients to developing kerion [47].
The age distribution in this cohort demonstrated the well-described epidemiology of tinea capitis with most of the patients being pre-pubertal, i.e., 3–7 years, but tinea capitis was also found in other age groups. This finding solidifies the fact that this cohort was a representative sample, and it allowed us to delve into the distribution of the different pathogens in these age groups. M. canis was not isolated in the cultures of patients older than 16 years of age, and it was most prevalent in patients younger than 10 years. Similarly, tinea capitis due to M. canis in adolescents is rarely described in the literature [48,49]. One hypothesis for this finding is the fact that infection with M. canis requires exposure to an animal reservoir such as cats and dogs, and it is possible that younger children have greater exposure to this potential infectious source. In addition, during puberty there is an increase in sebum excretion on the scalp. The triglycerides in the sebum have a fungistatic effect [50]. This effect might have a greater impact on M. canis than on T. tonsurans. Factors favoring infection with T. tonsurans in children over 10 years old should be further studied.
The treatment of T. tonsurans by terbinafine achieved the highest rate (95%) of complete clinical response, followed by a 68% response rate for fluconazole. Our study replicated encouraging responses for T. tonsurans treatment by terbinafine, rendering it as a first choice of treatment for T. tonsurans due to its considerably higher efficacy [16].
T. violaceum and M. canis responded similarly to griseofulvin with complete clinical response rates of 71% and 73%, respectively. These results are aligned with previous data [44]. Nevertheless, there are reports depicting a complete clinical cure for 46% of patients with tinea capitis worldwide [16]. Such a discrepancy might be attributed to the bioavailability of the drug prepared as a syrup in different pharmacies and to the significant influence of concomitant intake. Fluconazole was effective and achieved a clinical cure rate of 68–84% for M. canis and Trichophyton species, respectively. Previous studies varied in results, ranging from 40–45% of a complete clinical cure to almost 100% mycological cure [16,51,52]. Overall, we found that griseofulvin did not confer any therapeutic advantage over fluconazole (p = 0.44), supporting the use of either drug as a first-line treatment for M. canis, and as second-line treatments for T. tonsurans infections.
The limitations of this study include its retrospective design and regional relevance. In addition, similar to other tinea capitis studies, the choice of antifungal agent was affected by local availability [16]. Moreover, the microbiology sampling after treatment might have been affected by the level of suspicion of residual disease, and therefore was inconsistent. As our cohort was collected from outpatient dermatology clinics in tertiary hospitals, these patients may represent severe cases of tinea capitis, potentially caused by pathogens associated with more severe clinical phenotypes.

5. Conclusions

In conclusion, our study establishes a significant increase in the prevalence of tinea capitis due to T. tonsurans since 2019, turning it into the most common pathogen in our population. We also demonstrate that T. tonsurans is more common in males and highlight an inflammatory phenotype of this pathogen in a third of pediatric patients. These results emphasize the need to increase awareness of T. tonsurans among health professionals in order to efficiently control the spread of this emerging anthropophilic fungus.
Additionally, we show that M. canis still constitutes a major cause of tinea capitis, and continues to manifest at a stable prevalence, but is limited to children aged less than 15 years old. We also show the high efficacy of antifungal drugs among the pediatric population, with high rates of both clinical and mycological cures. We suggest that terbinafine should be considered the first choice of treatment for T. tonsurans infection, while griseofulvin and fluconazole show similar efficacy towards M. canis.

Author Contributions

Conceptualization and methodology, E.A.-H. and R.F.; formal analysis and visualization, J.D.; writing—original draft preparation, J.D., E.A.-H. and R.F.; writing—review and editing, J.D., E.A.-H., R.F., H.Z., Y.R.-Y. and Z.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Rambam Health Care Campus (497-20-RMB) and Schneider Children’s Medical Center (0654-19-RMC).

Informed Consent Statement

Patient consent was waived due to the retrospective nature of the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

The authors are appreciative of the respective laboratory units in Schneider Children’s Medical Center and Rambam Medical Health Center for their support during data collection.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Rodríguez-Cerdeira, C.; Martínez-Herrera, E.; Szepietowski, J.C.; Pinto-Almazán, R.; Frías-De-León, M.G.; Espinosa-Hernández, V.M.; Chávez-Gutiérrez, E.; García-Salazar, E.; Vega-Sánchez, D.C.; Arenas, R.; et al. A Systematic Review of Worldwide Data on Tinea Capitis: Analysis of the Last 20 Years. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 844–883. [Google Scholar] [CrossRef] [PubMed]
  2. Segal, E.; Elad, D. Human and Zoonotic Dermatophytoses: Epidemiological Aspects. Front. Microbiol. 2021, 12, 713532. [Google Scholar] [CrossRef] [PubMed]
  3. Mohta, A.; Singh, A.; Nyati, A.; Agrawal, A.; Nahar, D.; Lal, M.; Gupta, D.; Jain, S.K. Evaluation of Impact of Tinea Capitis on Quality of Life in Pediatric Patients Using Children’s Dermatology Life Quality Index and Its Correlation with Disease Duration. Int. J. Trichology 2020, 12, 213–219. [Google Scholar] [CrossRef] [PubMed]
  4. Mirmirani, P.; Tucker, L.-Y. Epidemiologic Trends in Pediatric Tinea Capitis: A Population-Based Study from Kaiser Permanente Northern California. J. Am. Acad. Dermatol. 2013, 69, 916–921. [Google Scholar] [CrossRef]
  5. Abdel-Rahman, S.M.; Farrand, N.; Schuenemann, E.; Stering, T.K.; Preuett, B.; Magie, R.; Campbell, A. The Prevalence of Infections with Trichophyton Tonsurans in Schoolchildren: The CAPITIS Study. Pediatrics 2010, 125, 966–973. [Google Scholar] [CrossRef]
  6. Aharaz, A.; Jemec, G.B.E.; Hay, R.J.; Saunte, D.M.L. Tinea capitis Asymptomatic Carriers: What Is the Evidence behind Treatment? J. Eur. Acad. Dermatol. Venereol. 2021, 35, 2199–2207. [Google Scholar] [CrossRef]
  7. Grijsen, M.L.; de Vries, H.J.C. Kerion. Can. Med. Assoc. J. 2017, 189, E725. [Google Scholar] [CrossRef] [Green Version]
  8. Zaraa, I.; Hawilo, A.; Aounallah, A.; Trojjet, S.; el Euch, D.; Mokni, M.; ben Osman, A. Inflammatory Tinea Capitis: A 12-Year Study and a Review of the Literature. Mycoses 2013, 56, 110–116. [Google Scholar] [CrossRef]
  9. Havlickova, B.; Czaika, V.A.; Friedrich, M. Epidemiological Trends in Skin Mycoses Worldwide. Mycoses 2008, 51, 2–15. [Google Scholar] [CrossRef]
  10. Lecerf, P.; Dangoisse, C.; van Ooteghem, A.; Vujovic, A.; Vollono, L.; Richert, B. Asymptomatic Scalp Carriage among Household Contacts of Children Affected by Tinea Capitis: A Prospective Study in the Metropolitan Area of Brussels, Belgium. Ski. Appendage Disord. 2022, 8, 200–205. [Google Scholar] [CrossRef]
  11. Ferguson, L.; Fuller, L.C. Spectrum and Burden of Dermatophytes in Children. J. Infect. 2017, 74, S54–S60. [Google Scholar] [CrossRef] [PubMed]
  12. Friedland, R.; Reiss-Huss, S.; Sabbah, F.; ben Amitai, D. Clinical Clues and Trends in Epidemiology and Pathogens in Paediatric Tinea Capitis: A Retrospective Cohort Study. Clin. Exp. Dermatol. 2022, 47, 50–56. [Google Scholar] [CrossRef] [PubMed]
  13. Shemer, A.; Gupta, A.K.; Galili, E.; Daniel, R.; Kassem, R.; Farhi, R.; Grunwald, H.; Bamimore, M.A. Management of Tinea capitis in Israel: A Comparative Study. Pediatr. Dermatol. 2021, 38, 806–811. [Google Scholar] [CrossRef] [PubMed]
  14. Bolognia, J.L.; Schaffer, J.V.; Cerroni, L. Dermatology: 2-Volume Set, 4th ed.; Elsevier: Amsterdam, The Netherlands, 2018; Volume 2, pp. 2229–2236. [Google Scholar]
  15. Gruseck, E.; Splanemann, V.; Bleck, O.; Ring, J.; Abeck, D. Oral Terbinafine in Tinea capitis in Children. Mycoses 1996, 39, 237–240. [Google Scholar] [CrossRef]
  16. Gupta, A.K.; Mays, R.R.; Versteeg, S.G.; Piraccini, B.M.; Shear, N.H.; Piguet, V.; Tosti, A.; Friedlander, S.F. Tinea capitis in Children: A Systematic Review of Management. J. Eur. Acad. Dermatol. Venereol. 2018, 32, 2264–2274. [Google Scholar] [CrossRef] [PubMed]
  17. Muhaj, F.F.; George, S.J.; Nguyen, C.D.; Tyring, S.K. Antimicrobials and Resistance Part II: Antifungals, Antivirals, and Antiparasitics. J. Am. Acad. Dermatol. 2022, 86, 1207–1226. [Google Scholar] [CrossRef]
  18. Chen, B.K.; Friedlander, S.F. Tinea capitis Update: A Continuing Conflict with an Old Adversary. Curr. Opin. Pediatr. 2001, 13, 331–335. [Google Scholar] [CrossRef]
  19. Bookstaver, P.B.; Watson, H.J.; Winters, S.D.; Carlson, A.L.; Schulz, R.M. Prophylactic Ketoconazole Shampoo for Tinea Capitis in a High-Risk Pediatric Population. J. Pediatr. Pharmacol. Ther. 2011, 16, 199–203. [Google Scholar] [CrossRef]
  20. Woodard, A.A.; Le, T.K.; DiBiagio, J.R.; Goldenberg, N.A.; Cohen, B.A. A Retrospective Study of Tinea capitis Management in General Pediatric Clinics and Pediatric Emergency Departments at 2 US Centers. J. Pediatr. 2021, 234, 269–272. [Google Scholar] [CrossRef]
  21. Sherman, S.; Goshen, M.; Treigerman, O.; Ben-Zion, K.; Carp, M.-J.; Maisler, N.; Ehrenreich, I.B.; Kimchi, A.; Lifshitz, S.; Smollan, G.; et al. Evaluation of Multiplex Real-Time PCR for Identifying Dermatophytes in Clinical Samples-A Multicentre Study. Mycoses 2018, 61, 119–126. [Google Scholar] [CrossRef]
  22. Hay, R.J. Tinea Capitis: Current Status. Mycopathologia 2017, 182, 87–93. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Magill, S.S.; Manfredi, L.; Swiderski, A.; Cohen, B.; Merz, W.G. Isolation of Trichophyton Violaceum and Trichophyton Soudanense in Baltimore, Maryland. J. Clin. Microbiol. 2007, 45, 461–465. [Google Scholar] [CrossRef] [Green Version]
  24. McPherson, M.E.; Woodgyer, A.J.; Simpson, K.; Chong, A.H. High Prevalence of Tinea capitis in Newly Arrived Migrants at an English-language School, Melbourne, 2005. Med. J. Aust. 2008, 189, 13–16. [Google Scholar] [CrossRef] [PubMed]
  25. Jankowska-Konsur, A.; Dyląg, M.; Szepietowski, J.C. Tinea capitis in Southwest Poland. Mycoses 2009, 52, 193–194. [Google Scholar] [CrossRef] [PubMed]
  26. Binder, B.; Lackner, H.K.; Poessl, B.D.; Propst, E.; Weger, W.; Smolle, J.; Ginter-Hanselmayer, G. Prevalence of Tinea capitis in Southeastern Austria between 1985 and 2008: Up-to-Date Picture of the Current Situation. Mycoses 2011, 54, 243–247. [Google Scholar] [CrossRef]
  27. Morales, E.G.; Iorizzo, M.; Lucchini, G.M.; Mainetti, C. Trichophyton Violaceum: An Emerging Pathogen in Southern Switzerland. Dermatology 2019, 235, 434–439. [Google Scholar] [CrossRef]
  28. Farina, C.; Fazii, P.; Imberti, G.; Lombardi, G.; Passera, M.; Andreoni, S.; Italian Association of Clinical Microbiology (AMCLI) Dermatophytes’ Study Group; AMCLI Dermatophytes’ Study Group. TrichphytonViolaceum and T. Soudanese: Re-Emerging Pathogens in Italy, 2005–2013. New Microbiol. 2015, 38, 409–415. [Google Scholar]
  29. Nasir, S.; Ralph, N.; O’Neill, C.; Cunney, R.; Lenane, P.; O’Donnell, B. Trends in Tinea capitis in an Irish Pediatric Population and a Comparison of Scalp Brushings Versus Scalp Scrapings as Methods of Investigation. Pediatr. Dermatol. 2014, 31, 622–623. [Google Scholar] [CrossRef]
  30. Gits-Muselli, M.; Benderdouche, M.; Hamane, S.; Mingui, A.; de Chauvin, M.F.; Guigue, N.; Picat, M.-Q.; Bourrat, E.; Petit, A.; Bagot, M.; et al. Continuous Increase of Trichophyton Tonsurans as a Cause of Tinea capitis in the Urban Area of Paris, France: A 5-Year-Long Study. Med. Mycol. 2016, 55, 476–484. [Google Scholar] [CrossRef] [Green Version]
  31. Ziegler, W.; Lempert, S.; Goebeler, M.; Kolb-Mäurer, A. Tinea Capitis: Temporal Shift in Pathogens and Epidemiology. JDDG J. Der Dtsch. Ges. 2016, 14, 818–825. [Google Scholar] [CrossRef]
  32. Ginter-Hanselmayer, G.; Weger, W.; Ilkit, M.; Smolle, J. Epidemiology of Tinea capitis in Europe: Current State and Changing Patterns. Mycoses 2007, 50, 6–13. [Google Scholar] [CrossRef] [PubMed]
  33. Marcoux, D.; Dang, J.; Auguste, H.; McCuaig, C.; Powell, J.; Hatami, A.; Maari, C.; le Meur, J.-B. Emergence of African Species of Dermatophytes in Tinea Capitis: A 17-Year Experience in a Montreal Pediatric Hospital. Pediatr. Dermatol. 2018, 35, 323–328. [Google Scholar] [CrossRef] [PubMed]
  34. Mapelli, E.T.M.; Cerri, A.; Bombonato, C.; Menni, S. Tinea capitis in the Paediatric Population in Milan, Italy: The Emergence of Trichophyton Violaceum. Mycopathologia 2013, 176, 243–246. [Google Scholar] [CrossRef] [PubMed]
  35. Gray, R.M.; Champagne, C.; Waghorn, D.; Ong, E.; Grabczynska, S.A.; Morris, J. Management of a Trichophyton Tonsurans Outbreak in a Day-Care Center. Pediatr. Dermatol. 2015, 32, 91–96. [Google Scholar] [CrossRef] [PubMed]
  36. Pilz, J.F.; Köberle, M.; Kain, A.; Seidl, P.; Zink, A.; Biedermann, T.; Pilz, A.C. Increasing Incidence of Trichophyton Tonsurans in Munich-A Single-Centre Observation. Mycoses 2023. [Google Scholar] [CrossRef]
  37. Coulibaly, O.; Thera, M.A.; Piarroux, R.; Doumbo, O.K.; Ranque, S. High Dermatophyte Contamination Levels in Hairdressing Salons of a West African Suburban Community. Mycoses 2015, 58, 65–68. [Google Scholar] [CrossRef]
  38. Müller, V.L.; Kappa-Markovi, K.; Hyun, J.; Georgas, D.; Silberfarb, G.; Paasch, U.; Uhrlaß, S.; Nenoff, P.; Schaller, J. Tinea capitis et Barbae Caused by Trichophyton Tonsurans: A Retrospective Cohort Study of an Infection Chain after Shavings in Barber Shops. Mycoses 2021, 64, 428–436. [Google Scholar] [CrossRef]
  39. White, J.; Higgins, E.; Fuller, L. Screening for Asymptomatic Carriage of Trichophyton Tonsurans in Household Contacts of Patients with Tinea Capitis: Results of 209 Patients from South London. J. Eur. Acad. Dermatol. Venereol. 2007, 21, 1061–1064. [Google Scholar] [CrossRef]
  40. Hiruma, J.; Ogawa, Y.; Hiruma, M. Trichophyton Tonsurans Infection in Japan: Epidemiology, Clinical Features, Diagnosis and Infection Control. J. Dermatol. 2015, 42, 245–249. [Google Scholar] [CrossRef]
  41. Shroba, J.; Olson-Burgess, C.; Preuett, B.; Abdel-Rahman, S.M. A Large Outbreak of Trichophyton Tonsurans among Health Care Workers in a Pediatric Hospital. Am. J. Infect. Control 2009, 37, 43–48. [Google Scholar] [CrossRef] [Green Version]
  42. Araya, S.; Tesfaye, B.; Fente, D. Epidemiology of Dermatophyte and Non-Dermatophyte Fungi Infection in Ethiopia. Clin. Cosmet. Investig. Dermatol. 2020, 13, 291–297. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Israel Central Bureau of Statistics. The Population of Ethiopian Origin in Israel: Selected Data Published on the Occasion of the Sigd Festival 2022. Available online: www.cbs.gov.il/he/mediarelease/DocLib/2022/371/11_22_371e.pdf (accessed on 2 February 2023).
  44. Mashiah, J.; Kutz, A.; ben Ami, R.; Savion, M.; Goldberg, I.; Or, T.G.; Zidan, O.; Sprecher, E.; Harel, A. Tinea capitis Outbreak among Paediatric Refugee Population, an Evolving Healthcare Challenge. Mycoses 2016, 59, 553–557. [Google Scholar] [CrossRef] [PubMed]
  45. Friedland, R.; Sabbah, F.; Reiss-Huss, S.; ben Amitai, D. Epidemiologic Features and Risk of Scarring in Pediatric Patients with Kerion Celsi. Pediatr. Dermatol. 2022, 39, 215–219. [Google Scholar] [CrossRef] [PubMed]
  46. Hryncewicz-Gwóźdź, A.; Beck-Jendroschek, V.; Brasch, J.; Kalinowska, K.; Jagielski, T. Tinea Capitis and Tinea Corporis with a Severe Inflammatory Response Due to Trichophyton Tonsurans. Acta Derm. Venereol. 2011, 91, 708–710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Abdel-Rahman, S.M.; Preuett, B.L. Genetic Predictors of Susceptibility to Cutaneous Fungal Infections: A Pilot Genome Wide Association Study to Refine a Candidate Gene Search. J. Dermatol. Sci. 2012, 67, 147–152. [Google Scholar] [CrossRef] [Green Version]
  48. Zienicke, H.C.; Korting, H.C.; Lukacs, A.; Braun-Falco, O. Dermatophytosis in Children and Adolescents: Epidemiological, Clinical, and Microbiological Aspects Changing with Age. J. Dermatol. 1991, 18, 438–446. [Google Scholar] [CrossRef]
  49. Gianni, C.; Betti, R.; Perotta, E.; Crosti, C. Tinea Capitis in Adults. Mycoses 1995, 38, 329–331. [Google Scholar] [CrossRef]
  50. Gupta, A.K.; Summerbell, R.C. Tinea Capitis. Med. Mycol. 2000, 38, 255–287. [Google Scholar] [CrossRef]
  51. Haedersdal, M.; Svejgaard, E. Once-Weekly Fluconazole in Children with Tinea capitis Due to Microsporum Canis. Acta Derm.-Venereol. 2005, 85, 177–178. [Google Scholar] [CrossRef] [Green Version]
  52. Foster, K.W.; Friedlander, S.F.; Panzer, H.; Ghannoum, M.A.; Elewski, B.E. A Randomized Controlled Trial Assessing the Efficacy of Fluconazole in the Treatment of Pediatric Tinea Capitis. J. Am. Acad. Dermatol. 2005, 53, 798–809. [Google Scholar] [CrossRef]
Jof 09 00366 g001 550
Figure 1. Annual incidence of tinea capitis per species.
Figure 1. Annual incidence of tinea capitis per species.
Jof 09 00366 g001
Jof 09 00366 g002 550
Figure 2. Age distribution of M. canis and T. tonsurans across study population. p < 0.001.
Figure 2. Age distribution of M. canis and T. tonsurans across study population. p < 0.001.
Jof 09 00366 g002
Table
Table 1. Demographic characteristics of study population.
Table 1. Demographic characteristics of study population.
Characteristics
Mean age (years ± SD)7.01 ± 4.14
Male (%)309 (68)
Ethnicity (%)
Jewish Caucasian 273 (60)
Arab descent106 (23)
Ethiopian descent 74 (16)
Residence in a rural area (%)67 (15)
Average time to diagnosis (months ± SD)3.15 ± 4.8
Table
Table 2. Prevalence of main pathogens by gender.
Table 2. Prevalence of main pathogens by gender.
Fungi/GenderMalesFemalesTotal Patients
Trichophyton tonsurans * (%)114 (36.9)26 (17.6)140 (30.7)
Microsporum canis * (%)121 (39.1)59 (40.1)180 (39.5)
Trichophyton violaceum * (%) 42 (13.6)49 (33.3)91 (20.0)
Trichophyton mentagrophytes (%)9 (2.9)2 (1.3)11 (2.4)
Trichophyton rubrum (%)4 (1.2)1 (0.6)5 (1.1)
Nannizzia gypsea (%)3 (0.9)1 (0.6)4 (0.9)
Microsporum audouinii (%)1 (0.3)2 (1.3)3 (0.7)
Trichophyton verrucosom (%)2 (0.6)1 (0.6)3 (0.7)
Trichophyton soudanense (%)1 (0.3)1 (0.6)2 (0.4)
Unknown (%)11 (3.6)6 (4)17 (3.7)
Total309 147 456
* Statistical analysis was performed for the 3 most common pathogens (T. tonsurans, M. canis, and T. violaceum), p-value < 0.001.
Table
Table 3. Prevalence of main pathogens by ethnicity.
Table 3. Prevalence of main pathogens by ethnicity.
Fungi/EthnicityCaucasiansArabsEthiopiansAll Patients
T. Tonsurans * (%)108 (40)24 (22)8 (11)140
M. Canis * (%)112 (41)61 (56)7 (9)180
T. Violaceum * (%)22 (8)12 (10)57 (76)91
Other fungi (%)31 (11)11 (10)3 (4)45
Total 27310875456
* Statistical analysis was performed for the 3 most common pathogens (T. tonsurans, M. canis, and T. violaceum), p-value < 0.001.
Table
Table 4. Patients’ response per fungi to the respective oral regimen.
Table 4. Patients’ response per fungi to the respective oral regimen.
FungiAntifungal AgentCR (%)PR (%)NR (%)MC (%)
T. tonsurans * (n = 77)Griseofulvin (n = 13)5 (38)4 (31)4 (31)3/3 (100)
Fluconazole (n = 44)30 (68)9 (20)5 (11)12/17 (71)
Terbinafine (n = 20)19 (95)1 (5)0 (0)5/5 (100)
M. canis (n = 111)Griseofulvin (n = 48)35 (73)4 (8)9 (19)17/23 (74)
Fluconazole (n = 59)39 (66)9 (15)11 (19)11/23 (48)
Terbinafine (n = 4)0 (0)1 (25)3 (75)0/3 (0)
T. violaceum (n = 34)Griseofulvin (n = 14)10 (71)4 (29)0 (0)3/5 (60)
Fluconazole (n = 19)16 (84)2 (11)1 (5)4/5 (80)
Terbinafine (n = 1)0 (0)1 (100)0 (0)0
CR: complete response, PR: partial response, NR: no response, MC: mycological cure. * Statistically significant, p < 0.001.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Dascalu, J.; Zaaroura, H.; Renert-Yuval, Y.; Khamaysi, Z.; Avitan-Hersh, E.; Friedland, R. Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021. J. Fungi 2023, 9, 366. https://doi.org/10.3390/jof9030366

AMA Style

Dascalu J, Zaaroura H, Renert-Yuval Y, Khamaysi Z, Avitan-Hersh E, Friedland R. Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021. Journal of Fungi. 2023; 9(3):366. https://doi.org/10.3390/jof9030366

Chicago/Turabian Style

Dascalu, Joel, Hiba Zaaroura, Yael Renert-Yuval, Ziyad Khamaysi, Emily Avitan-Hersh, and Rivka Friedland. 2023. "Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021" Journal of Fungi 9, no. 3: 366. https://doi.org/10.3390/jof9030366

APA Style

Dascalu, J., Zaaroura, H., Renert-Yuval, Y., Khamaysi, Z., Avitan-Hersh, E., & Friedland, R. (2023). Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021. Journal of Fungi, 9(3), 366. https://doi.org/10.3390/jof9030366

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop